No abstract

Se estudió la calidad de vida relacionada con la salud de 49 heroinómanos que llevaban 4 años de tratamiento en un PMM en Asturias, utilizando el SF-36. Además, la severidad de la adicción se midió con el EuropASI, y la sintomatología depresiva y/o ansiosa con la Escala de Ansiedad-Depresión de Goldberg (EADG). Los pacientes mostraron una calidad de vida moderada, peor en las escalas del componente mental que en las del componente físicos (

We analyzed in a sample of 142 Centers of Drug Abuse and Alcoholism, in 11 regions of Spain, the programs that they carry out for smoking cessation. The 55.6% of centers carries out treatment of smokers. Along the year 2004 in this centers had a treatment demand of 3,771 smokers, 3,000 were treated, concluding the treatment half of them. The levels of abstinence for the end of the treatment and in the 6-and 12-months followup are good, in relation to the published clinical studies. The most utilized treatment are the combined (psychological and pharmacological) followed by the psychological treatment. They are usually apply by diferent professionals as therapits. They indicate several limitations to carry out this treatment, included usual in any addiction (e.g., the smokers' low motivation), lack of time, limited personal, etc. They appreciates a clear increment of the demand, so much of people that they go with single nicotine dependence like of its classic users that are to treatment for other dependences. This data indicated the professional relevance of Centers of Drug Dependence in the treatment of nicotine dependence and the high effectiveness of the treatments that carry out with the smokers. They consider necessary that they have more means to make in front of the continuous increment of demand that they are having for the treatment of the nicotine dependence in their centers.

IntroductionThis experimental trial aims to describe the experiences felt by a group of patients diagnosed with different psychotic disorders (schizophrenia, delusional chronic disorder, etc.) in which the use of Benzodiazepine derivatives were related to emergence of lucid dreaming and dissociative events (to see oneself out of your one body, etc.), and to a lesser extent had subsequent depressive symptoms. Fifty-six patients were monitored and linked to the emergence of depressive symptoms related to the use of Benzodiazepines or sedative-hypnotic. While on this treatment, they had vivid or lucid dreaming.Aims-objectivesTo explore the relationship between occurrence of drug dreams (DDs) and daytime negative affect with lucid awakening during the course of a 9-week treatment.MethodsUsing the dream journal methodology, 56 participants reported occurrence of dreams, dream content, and ratings of affect. The relationships between the experience of DD, dream content (“active” vs “passive”), and affect were analysed using mixed model methods.ResultsThe experience of DD was associated with higher levels of negative affect (P < 0.001). The occurrence of DD did not decrease significantly over the 9 weeks of the study. Benzodiazepine users reported a higher occurrence of Lucid Awakening (P < 0.05) than the other drug groups (zolpidem and clometiazol).ConclusionsThese results are consistent with the hypothesis that DD can act as drug-conditioned stimuli to elevate negative affect. Although correlational, such findings support the implementation of psychological and pharmacological interventions aimed at minimizing the impact of DD on patients with lucid awakening and psychosis.Disclosure of interestThe authors have not supplied their declaration of competing interest.